Solaxa Inc. Appoints Brad Navia, MD, PhD as Chief Medical Officer
Solaxa Inc. Appoints Brad Navia, MD, PhD as Chief Medical Officer Bethesda, MD; June 27, 2026 – Solaxa Inc. announces […]
Solaxa Inc. Appoints Bill Passer, MBA, as Chief Financial Officer
Solaxa Inc. Appoints Bill Passer, MBA, as Chief Financial Officer Bethesda, MD; May 15, 2026 – Solaxa Inc. announces that
Press
Solaxa and Alvogen enter into $95M license agreement for the development and commercialization of SLX-100
Bethesda, MD and Morristown, NJ, February 23, 2026 — Alvogen, a US-based wholly owned subsidiary of Lotus Pharmaceutical Co., Ltd. (TWSE:
Press
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B Bethesda, MD — March 28, 2025 – Solaxa Inc.,
Press
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100
Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100 Bethesda, MD; January 6, 2024 – Solaxa Inc. announces today
Press
Solaxa Inc. Collaborates with National Ataxia Foundation
Solaxa Inc. Collaborates with National Ataxia Foundation Bethesda, MD and Minneapolis, MN; September 25, 2024 – On International Ataxia Awareness
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer
Solaxa Inc. Appoints Kerry Clem as Chief Commercial Officer Bethesda, MD; August 19, 2024 – Solaxa Inc. announces that Kerry
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc.
U.S. Food and Drug Administration Grants Orphan Drug Designation to Solaxa Inc. Bethesda, MD; July 26, 2024 – Solaxa Inc.
TEDCO Announces SSBCI Investment in Solaxa Inc.
TEDCO Announces SSBCI Investment in Solaxa Inc. Maryland-based biopharmaceutical company receives funding from TEDCO’s Venture Funds COLUMBIA, Md., (July 23,
Maryland Tech Council Announces Winners of 2024 ICON Awards
The Maryland Tech Council (MTC), the largest technology and life sciences trade association in the state, today announced the winners